5QIJ

CRYSTAL STRUCTURE OF MURINE 11B- HYDROXYSTEROIDDEHYDROGENASE COMPLEXED WITH 2-(3-(1-(4- CHLOROPHENYL)CYCLOPROPYL)-[1,2,4]TRIAZOLO[4,3-A]PYRIDIN-8- YL)PROPAN-2-OL

5QIJ の概要

• エントリーDOI: 10.2210/pdb5qij/pdb
• Group deposition: 11betaHSD1 (G_1002051)
• 分子名称: Corticosteroid 11-beta-dehydrogenase isozyme 1, NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, 2-{3-[1-(4-chlorophenyl)cyclopropyl][1,2,4]triazolo[4,3-a]pyridin-8-yl}propan-2-ol, ... (5 entities in total)
• 機能のキーワード: 11b-hsd1, sdr, dehydrogenase, hydroxysteroid, inhibitor, oxidoreductase-oxidoreductase inhibitor complex, oxidoreductase/oxidoreductase inhibitor
• 由来する生物種: Mus musculus (Mouse)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 64641.84

構造登録者

Sheriff, S. (登録日: 2018-07-03, 公開日: 2018-12-19, 最終更新日: 2026-02-18)

主引用文献

Li, J.,Kennedy, L.J.,Walker, S.J.,Wang, H.,Li, J.J.,Hong, Z.,O'Connor, S.P.,Ye, X.Y.,Chen, S.,Wu, S.,Yoon, D.S.,Nayeem, A.,Camac, D.M.,Ramamurthy, V.,Morin, P.E.,Sheriff, S.,Wang, M.,Harper, T.W.,Golla, R.,Seethala, R.,Harrity, T.,Ponticiello, R.P.,Morgan, N.N.,Taylor, J.R.,Zebo, R.,Maxwell, B.,Moulin, F.,Gordon, D.A.,Robl, J.A.
Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11 beta-Hydroxysteroid Dehydrogenase Type 1 (11 beta-HSD-1).
ACS Med Chem Lett, 9:1170-1174, 2018

PubMed Abstract: BMS-823778 (), a 1,2,4-triazolopyridinyl-methanol derived analog, was identified as a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) enzyme (IC = 2.3 nM) with >10,000-fold selectivity over 11β-HSD-2. Compound exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED = 0.6 mg/kg) and in diet-induced obese (DIO) mice (ED = 34 mg/kg). Compound also showed excellent inhibition in an adipose DIO mouse model (ED = 5.2 mg/kg). Oral bioavailability ranges from 44% to 100% in preclinical species. Its favorable development properties, pharmacokinetics, high adipose-to-plasma concentration ratio, and preclinical pharmacology profile have prompted the evaluation of for the treatment of type 2 diabetes and metabolic syndrome in phase 2 clinical trials.

PubMed: 30613321
DOI: 10.1021/acsmedchemlett.8b00307

実験手法

X-RAY DIFFRACTION (2.65 Å)